Pre-treatment radiomics from radiotherapy dose regions predict distant brain metastases in stereotactic radiosurgery

Joseph Bae; Renee Cattell; Ewa Zabrocka; John Roberson; David Payne; Kartik Mani; Prateek Prasanna

doi:10.1117/12.2612088

4 April 2022 Pre-treatment radiomics from radiotherapy dose regions predict distant brain metastases in stereotactic radiosurgery

Joseph Bae, Renee Cattell, Ewa Zabrocka, John Roberson, David Payne, Kartik Mani, Prateek Prasanna

Author Affiliations +

Proceedings Volume 12031, Medical Imaging 2022: Physics of Medical Imaging; 120311O (2022) https://doi.org/10.1117/12.2612088
Event: SPIE Medical Imaging, 2022, San Diego, California, United States

Abstract

Stereotactic radiosurgery (SRS) is frequently employed to treat brain metastases. However, <50% of patients treated with this method develop distant brain metastases (DBMs). As a result, these patients are followed using Magnetic Resonance Imaging (MRI) to identify DBM development. There is no current pre-treatment risk metric to identify which patients might be likely to develop DBMs. In this study, pre-treatment MRIs and radiotherapy planning data including structure sets and radiation dose maps were obtained for 81 SRS brain metastases treatment courses. Clinical variables including performance status, age, number of tumors, and primary tumor type were also collected. Pre-treatment MRIs were skull-stripped and normalized. 3D radiomic features from grey-intensity, Laws Energy, Gabor, Haralick, and CoLlAGe feature families were extracted from T1, T1 contrast-enhanced (T1w), T2, and FLAIR pre-treatment MRI sequences in brain regions receiving 0-25%, 25-50%, 50-75%, and 75-100% of prescribed radiation dose. A baseline classification model for DBM was created using clinical variables. Ablation studies were performed to determine which dose region and MRI sequence contained radiomic features most predictive for DBM development using machine learning (ML) classifiers. An ML classifier trained on 3D radiomic features from the 50-75% dose region of pre-treatment T1w MRI (AUC: 0.71, 95% CI: 0.68-0.74) outperformed the baseline model (AUC: 0.50, 95% CI: 0.47-0.53) for DBM prediction. In conclusion, we leverage radiotherapy dose regions to identify subcompartments for radiomic feature extraction from multi-parametric pre-treatment MRI data. We demonstrate that radiomic features from these dose regions can be used to predict DBM for SRS-treated brain metastases.

Conference Presentation

Citation Download Citation

Joseph Bae, Renee Cattell, Ewa Zabrocka, John Roberson, David Payne, Kartik Mani, and Prateek Prasanna "Pre-treatment radiomics from radiotherapy dose regions predict distant brain metastases in stereotactic radiosurgery", Proc. SPIE 12031, Medical Imaging 2022: Physics of Medical Imaging, 120311O (4 April 2022); https://doi.org/10.1117/12.2612088

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available